CHINARES PHARMA: 5 products under its umbrella are expected to be selected for the 11th batch of national drug procurement

CHINARES PHARMA (03320.HK) announced that recently, multiple subsidiaries under CHINARES PHARMA participated in the 11th national centralized procurement organized by the Joint Procurement Office, with a total of five products from the group expected to be selected in this procurement.

The products selected by the group involve multiple treatment and disease areas, including cardiovascular, nervous system, digestive tract, and metabolism. These include the hydrochloride methochlorpromazine injection from CHINARES SHUANGHE (600062.SH), the mesylate injection, famotidine injection, and piracetam tablets from CHINARES SHUANGHE Limin Pharmaceutical (Jinan), as well as the nicardipine tablets from Tian Shi Li Pharmaceutical (600535.SH).

In 2024, the sales revenue for famotidine injection was RMB 5.4807 million, nicardipine tablets sales revenue was RMB 596,600, and piracetam tablets sales revenue was RMB 124,100. The hydrochloride methochlorpromazine injection and mesylate injection have not generated market sales since 2024.

This drug procurement is the 11th batch of national drug procurement organized by the state. During the procurement period, medical institutions will prioritize the use of the selected drugs from this procurement and ensure the completion of the agreed procurement volume. The determination of selected products, signing of purchase and sales contracts, and implementation will help increase the market share of related products, enhance the brand influence of the group's pharmaceutical business, and have a positive impact on CHINARES PHARMA's future operating performance